The combination of L19-IL-2 and L19-TNF was also tested in a phase II clinical trial, in which this treatment showed remarkable efficacy in eradicating non-injected melanoma lesions (7/13 lesions) [83]. The gene discussed is IL2; the disease is melanoma.